3D bioprinting leader Organovo has been steadily growing this year, signing deals with pharmaceutical giant Merck and cosmetics company L’Oreal, as well as releasing news related to their first 3D printed kidney tissue. Given these big partnerships, then, it strikes me as a bit odd that the company is looking for more money.
Yesterday, the company announced the sale of 9,425,000 shares of common stock at $4.25 per share, with underwriters given a 30-day option to buy an additional 1,413,750 shares.…
The original post Update: Organovo Justifies Secondary Stock Offering with Goals of $400M+ in Bioprinting Profits appeared first on 3D Printing Industry.